Soflax100 mg

Soflax is an emollient (surfactant-type) laxative used for the prevention and short-term treatment of occasional constipation. Its indications can be classified by strength of evidence as follows:

Established / Widely Accepted Uses

• Prevention and relief of occasional constipation by softening hard, dry stool.
• Situations where straining during bowel movements should be avoided, such as after abdominal or rectal surgery, after myocardial infarction, in patients with hemorrhoids or anal fissures, and during the postpartum period.
• Facilitating comfortable bowel movements in bedridden or immobile patients.

Adjunct / Combination Use

• Soflax is not a stimulant laxative and does not significantly increase bowel motility. For constipation that does not respond to stool softening alone (e.g., opioid-induced constipation), Soflax is often combined with a stimulant laxative (such as senna) rather than used alone.

Soflax is not intended for long-term, unsupervised use in chronic constipation without medical evaluation of the underlying cause.

Each dosage unit of Docusate Sodium contains docusate sodium (dioctyl sodium sulfosuccinate) as the active ingredient. Docusate Sodium is commonly available as:

• Oral capsules/softgels: 50 mg, 100 mg, and 250 mg
• Oral liquid/syrup: various strengths (e.g., 10 mg/mL or 50 mg/5 mL)
• Rectal enema/suppository preparations in some markets

Inactive ingredients vary by manufacturer and formulation and may include gelatin, glycerin, polyethylene glycol, sorbitol, and flavoring/coloring agents.

Soflax is an anionic surfactant (detergent-like) compound classified as a stool softener or emollient laxative. Unlike stimulant laxatives, Soflax does not directly stimulate intestinal muscle contraction. Instead, it works locally by lowering the surface tension at the interface between stool and intestinal fluid, allowing water and fats to penetrate and mix into the stool.

This results in a softer, easier-to-pass stool without significantly increasing the frequency or urgency of bowel movements. Soflax has minimal systemic absorption and is generally considered a mild, well-tolerated option for preventing straining during defecation.

Soflax belongs to the therapeutic class of laxatives, specifically the stool softener (emollient/surfactant laxative) subclass, distinct from stimulant, osmotic, and bulk-forming laxatives.

Mechanism of Action

Docusate Sodium acts as an anionic surfactant within the intestinal lumen. It reduces the surface tension of the stool mass, permitting water and lipids from the intestinal contents to penetrate and soften the stool. It also mildly promotes fluid and electrolyte secretion into the small and large bowel, which contributes to softer stool consistency.

Pharmacokinetics

Docusate Sodium is minimally absorbed systemically. A small proportion may be absorbed from the small intestine, partially metabolized in the liver, and excreted in bile, while the majority acts locally within the gut and is eliminated in the feces. Onset of action typically occurs within 12 to 72 hours after the first dose.

Soflax capsules and softgels should be swallowed whole with a full glass of water or other liquid; they should not be chewed, as Soflax may cause throat irritation. Oral liquid formulations of Soflax may be taken directly or mixed with milk, fruit juice, or infant formula to mask the bitter taste. Soflax may be taken with or without food. Rectal formulations, where available, should be used strictly as directed on the product label.

Mineral oil: Concurrent use of Soflax with mineral oil is generally discouraged, as Soflax's surfactant action may theoretically increase systemic absorption of mineral oil, which has historically raised concern (though clinical significance is debated). Avoid combining Soflax with mineral oil unless specifically directed by a physician.

As a surfactant, Soflax could theoretically alter the absorption of other orally co-administered drugs, though this is not well established as clinically significant for most medications. No other major, well-verified drug interactions are established for Soflax.

Soflax is generally very mild and well tolerated due to minimal systemic absorption. Reported side effects include:

• Mild abdominal/intestinal cramping
• Diarrhea or loose stools, particularly with higher doses
• Nausea
• Throat irritation (if capsules are chewed rather than swallowed whole)
• Rash or other hypersensitivity reactions (rare)

Serious side effects from Soflax are uncommon. Patients should stop use and consult a physician if rectal bleeding occurs or if there is no bowel movement after use, as this may suggest a more serious underlying problem.

Soflax has minimal systemic absorption and is commonly used during pregnancy and lactation for constipation when non-pharmacologic measures (fluids, fiber, activity) are insufficient. However, as with all medications, Soflax should be used during pregnancy or breastfeeding only if clearly needed, and a physician or pharmacist should be consulted before use to weigh potential benefit against any potential risk.

• Soflax should not be used for more than one week continuously without medical advice; prolonged unsupervised use of any laxative may mask an underlying gastrointestinal disorder.
• Discontinue Soflax and consult a physician if abdominal pain, nausea, or vomiting develops, or if rectal bleeding occurs or no bowel movement results after use (see Contraindications).
• Avoid concurrent use of Soflax with mineral oil unless directed by a physician (see Interactions).
• Soflax is not effective as a stimulant laxative; it does not increase bowel motility and may need to be combined with a stimulant laxative for constipation that does not respond to stool softening alone.
• Use caution and seek medical advice before giving Soflax to very young children or if constipation is chronic or recurrent, as an underlying cause should be evaluated.

Overdose with Soflax is generally expected to cause diarrhea and, with excessive or prolonged use, potential fluid and electrolyte imbalance. There is no specific antidote for Soflax overdose. If overdose is suspected, contact a physician, poison control center, or emergency services immediately for guidance rather than attempting specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Soflax is commonly used in elderly patients, who are at higher risk of constipation, and is generally well tolerated due to minimal systemic absorption; no specific dose adjustment is typically required.

Renal Impairment

No specific dose adjustment of Soflax is established as necessary in renal impairment, given minimal systemic absorption; use with routine caution.

Hepatic Impairment

No specific dose adjustment of Soflax is established as necessary in hepatic impairment; use with routine caution.

Pediatric Patients

See Pediatric Uses for age-based dosing information.

Soflax is generally intended for short-term or as-needed use. It should not be used continuously for more than one week without medical advice; if constipation persists beyond this period, a physician should evaluate for an underlying cause before continuing Soflax.

Docusate Sodium belongs to the laxative drug class, specifically categorized as a stool softener, emollient laxative, or surfactant (anionic detergent-type) laxative.

Docusate Sodium acts as an anionic surfactant that reduces the surface tension of stool, allowing water and fat to penetrate and mix into the fecal mass, producing a softer stool that is easier to pass without significantly increasing intestinal motility.

C

Soflax may be used in children for occasional constipation, with dosing based on age:

• Children 12 years and older: dosed as adults, 50 mg to 300 mg per day.
• Children 6 to under 12 years: 40 mg to 150 mg per day.
• Children 2 to under 6 years: 20 mg to 60 mg per day.
• Children under 2 years: safety and efficacy of Soflax have not been well established; use only under direct physician supervision.

Soflax liquid formulations may be mixed with milk, juice, or infant formula to improve palatability in younger children. Chewable or capsule forms should not be given to children who cannot reliably swallow them whole.